aspartylglucosaminuria

Showing 1 posts of 1 posts found.

european_commission

Neurogene secures EMA orphan designation for gene therapy in rare, inherited aspartylglucosaminuria

December 3, 2020
Sales and Marketing EMA, Neurogene, aspartylglucosaminuria

The European Medicines Agency (EMA) has bestowed Orphan Drug Designation (ODD) to Neurogene’s adeno-associated virus vector (AAV) gene therapy in …

The Gateway to Local Adoption Series

Latest content